GT Biopharma Inc expected to post a loss of 68 cents a share - Earnings Preview

GT Biopharma

08/08/2025 13:53

GT Biopharma Inc GTBP.OQ GTBP.O is expected to  report resultson August 12 (estimated) for the period ending June 30 2025

​LSEG's mean analyst estimate for GT Biopharma Inc is for a loss of 68 cents per share.

The one available analyst rating on the shares is "buy".

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for GT Biopharma Inc is $11.00, about 83.4% above its last closing price of $1.83

This summary was machine generated August 8 at 12:53 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)